FDA’s ‘Green List’ Surrendered GLP-1 Supply to China

0
113

The U.S. Food and Drug Administration (FDA) has enabled China to corner the market on GLP-1 obesity drugs to the detriment of the safety of Americans, RX Border Defense’s Patsy Writesman told Breitbart News Washington Bureau Chief Matthew Boyle on Thursday during an event on the threat of China.

Writesman discussed how the FDA put many Chinese companies that produce GLP-1 drugs on a “Green List,” which means they are “not being detained at the border.” She contended that the government-created loophole to flood the market with obesity drugs creates an environment where Americans have access to drugs that may have been created under lax safety standards or lack transparency around ingredients.

“Over 50 percent of those companies [not being detained] are Chinese companies,” said Writesman, a board member of RX Border Defense, which is a nonprofit organization…

Read more…

LEAVE A REPLY

Please enter your comment!
Please enter your name here